Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Schering-Plough Adds Levitra To Product Portfolio Through Deal With Bayer

This article was originally published in The Pink Sheet Daily

Executive Summary

Bayer abandons primary care market in U.S. and will cut 1,800 sales positions. Schering-Plough will take over marketing of Avelox and Cipro as well as Bayer's portion of Levitra co-promotion efforts.

You may also be interested in...



DTC Advertising "Tone-Down" Could Address FDA Concerns, Schering Says

Marketers will begin airing more balanced DTC ads as a result of increased scrutiny from FDA about the quality of some ads, Schering CFO Bertolini says. With Levitra, Schering now participates in what may be a high-risk market for DTC ads: erectile dysfunction disorder.

DTC Advertising "Tone-Down" Could Address FDA Concerns, Schering Says

Marketers will begin airing more balanced DTC ads as a result of increased scrutiny from FDA about the quality of some ads, Schering CFO Bertolini says. With Levitra, Schering now participates in what may be a high-risk market for DTC ads: erectile dysfunction disorder.

Phase III Antibiotic Garenoxacin Will Be Out-Licensed, Schering Says

Schering-Plough will out-license U.S. rights to the Phase III quinolone antibiotic garenoxacin due to potential conflicts of interest related to the company's primary care marketing agreement with Bayer

Related Content

Topics

UsernamePublicRestriction

Register

GB150348

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel